Table of Contents Author Guidelines Submit a Manuscript
Pulmonary Medicine
Volume 2011, Article ID 872120, 12 pages
http://dx.doi.org/10.1155/2011/872120
Review Article

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Diagnostic Dilemma

Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, 5th Floor, Baltimore, MD 21205, USA

Received 21 October 2010; Revised 1 March 2011; Accepted 24 March 2011

Academic Editor: D. Bouros

Copyright © 2011 Mark J. Hamblin and Maureen R. Horton. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Fujii, S. Adachi, T. Shimizu, S. Hiroto, M. Sako, and M. Kono, “Interstitial lung disease in rheumatoid arthritis: assessment with high-resolution computed tomography,” Journal of Thoracic Imaging, vol. 8, no. 1, pp. 54–62, 1993. View at Google Scholar · View at Scopus
  2. E. Gabbay, R. Tarala, R. Will et al., “Interstitial lung disease in recent onset rheumatoid arthritis,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 2, part 1, pp. 528–535, 1997. View at Google Scholar · View at Scopus
  3. H. Toyoshima, T. Kusaba, and M. Yamaguchi, “Cause of death in autopsied RA patients,” Ryumachi, vol. 33, no. 3, pp. 209–214, 1993. View at Google Scholar · View at Scopus
  4. J. McDonagh, M. Greaves, A. R. Wright, C. Heycock, J. P. Owen, and C. Kelly, “High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease,” British Journal of Rheumatology, vol. 33, no. 2, pp. 118–122, 1994. View at Google Scholar · View at Scopus
  5. B. R. Gochuico, N. A. Avila, C. K. Chow et al., “Progressive preclinical interstitial lung disease in rheumatoid arthritis,” Archives of Internal Medicine, vol. 168, no. 2, pp. 159–166, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. C. Morrison, G. M. Mody, S. R. Benatar, and O. L. Meyers, “The lungs in rheumatoid arthritis—a clinical, radiographic and pulmonary function study,” South African Medical Journal, vol. 86, no. 7, pp. 829–833, 1996. View at Google Scholar · View at Scopus
  7. W. C. Walker and V. Wright, “Pulmonary lesions and rheumatoid arthritis,” Medicine, vol. 47, no. 6, pp. 501–520, 1968. View at Google Scholar · View at Scopus
  8. P. Cervantes-Perez, A. H. Toro-Perez, and P. Rodriguez-Jurado, “Pulmonary involvement in rheumatoid arthritis,” Journal of the American Medical Association, vol. 243, no. 17, pp. 1715–1719, 1980. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Cortet, R. M. Flipo, M. Remy-Jardin et al., “Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 54, no. 10, pp. 815–819, 1995. View at Google Scholar · View at Scopus
  10. J. K. Dawson, H. E. Fewins, J. Desmond, M. P. Lynch, and D. R. Graham, “Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests,” Thorax, vol. 56, no. 8, pp. 622–627, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Geddes, M. Webley, and P. A. Emerson, “Airways obstruction in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 38, no. 3, pp. 222–225, 1979. View at Google Scholar · View at Scopus
  12. A. Vergnenègre, N. Pugnere, M. T. Antonini et al., “Airway obstruction and rheumatoid arthritis,” European Respiratory Journal, vol. 10, no. 5, pp. 1072–1078, 1997. View at Google Scholar · View at Scopus
  13. R. H. Lofgren and W. W. Montgomery, “Incidence of laryngeal involvement in rheumatoid arthritis,” The New England Journal of Medicine, vol. 267, pp. 193–195, 1962. View at Google Scholar
  14. V. Cottin, H. Nunes, P. Y. Brillet et al., “Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity,” European Respiratory Journal, vol. 26, no. 4, pp. 586–593, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. F. Aduen, D. A. Zisman, S. I. Mobin et al., “Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease,” Mayo Clinic Proceedings, vol. 82, no. 1, pp. 48–54, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. L. Schmidt et al., “Pulmonary function measures predict mortality differently in idiopathic pulmonary fibrosis versus combined pulmonary fibrosis and emphysema,” European Respiratory Journal. In press.
  17. S. A. Albano, E. Santana-Sahagun, and M. H. Weisman, “Cigarette smoking and rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 31, no. 3, pp. 146–159, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. E. J. Kim, H. R. Collard, and T. E. King Jr., “Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern,” Chest, vol. 136, no. 5, pp. 1397–1405, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. D. E. O'Donnell, J. Ora, K. A. Webb, P. Laveneziana, and D. Jensen, “Mechanisms of activity-related dyspnea in pulmonary diseases,” Respiratory Physiology and Neurobiology, vol. 167, no. 1, pp. 116–132, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. M. Weyand, D. Schmidt, U. Wagner, and J. J. Goronzy, “The influence of sex on the phenotype of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 41, no. 5, pp. 817–822, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. K. G. Saag, S. Kolluri, R. K. Koehnke et al., “Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities,” Arthritis and Rheumatism, vol. 39, no. 10, pp. 1711–1719, 1996. View at Google Scholar · View at Scopus
  22. I. Alexiou, A. Germenis, A. Koutroumpas, A. Kontogianni, K. Theodoridou, and L. I. Sakkas, “Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 27, no. 4, pp. 511–513, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. N. Tanaka, J. S. Kim, J. D. Newell et al., “Rheumatoid arthritis-related lung diseases: CT findings,” Radiology, vol. 232, no. 1, pp. 81–91, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. M. Akira, M. Sakatani, and H. Hara, “Thin-section CT findings in rheumatoid arthritis-associated lung disease: CT patterns and their courses,” Journal of Computer Assisted Tomography, vol. 23, no. 6, pp. 941–948, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. E. S. White, H. D. Tazelaar, and J. P. Lynch III, “Bronchiolar complications of connective tissue diseases,” Seminars in Respiratory and Critical Care Medicine, vol. 24, no. 5, pp. 543–565, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. H. K. Lee, D. S. Kim, B. Yoo et al., “Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease,” Chest, vol. 127, no. 6, pp. 2019–2027, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. D. Tansey, A. U. Wells, T. V. Colby et al., “Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis,” Histopathology, vol. 44, no. 6, pp. 585–596, 2004. View at Publisher · View at Google Scholar · View at PubMed
  28. A. Rajasekaran, D. Shovlin, V. Saravanan, P. Lord, and C. Kelly, “Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years,” Journal of Rheumatology, vol. 33, no. 7, pp. 1250–1253, 2006. View at Google Scholar · View at Scopus
  29. J. H. Park, D. S. Kim, I. N. Park et al., “Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 7, pp. 705–711, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. W. D. Travis, K. Matsui, J. Moss, and V. J. Ferrans, “Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns—survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia,” American Journal of Surgical Pathology, vol. 24, no. 1, pp. 19–33, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Biederer, A. Schnabel, C. Muhle, W. L. Gross, M. Heller, and M. Reuter, “Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis,” European Radiology, vol. 14, no. 2, pp. 272–280, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. W. D. Travis, G. Hunninghake, T. E. King et al., “Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society Project,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 12, pp. 1338–1347, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. H. Hayakawa, A. Sato, S. Imokawa, M. Toyoshima, K. Chida, and M. Iwata, “Bronchiolar disease in rheumatoid arthritis,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 5, pp. 1531–1536, 1996. View at Google Scholar · View at Scopus
  34. American Thoracic Society (ATS), and the European Respiratory Society (ERS), “American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 2, pp. 277–304, 2002. View at Google Scholar
  35. J. H. Park, D. K. Kim, D. S. Kim et al., “Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia,” European Journal of Cardio-thoracic Surgery, vol. 31, no. 6, pp. 1115–1119, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. C. Turesson, L. Jacobsson, and U. Bergström, “Extra-articular rheumatoid arthritis: prevalence and mortality,” Rheumatology, vol. 38, no. 7, pp. 668–674, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Suzuki, Y. Ohosone, M. Obana et al., “Cause of death in 81 autopsied patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 21, no. 1, pp. 33–36, 1994. View at Google Scholar · View at Scopus
  38. F. Wolfe, L. Caplan, and K. Michaud, “Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy,” Arthritis and Rheumatism, vol. 54, no. 2, pp. 628–634, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. S. H. Yale and A. H. Limper, “Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy,” Mayo Clinic Proceedings, vol. 71, no. 1, pp. 5–13, 1996. View at Google Scholar · View at Scopus
  40. J. J. Gómez-Reino, L. Carmona, V. Rodríguez Valverde, E. M. Mola, and M. D. Montero, “Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report,” Arthritis and Rheumatism, vol. 48, no. 8, pp. 2122–2127, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. L. P. Ormerod, H. J. Milburn, S. Gillespie, J. Ledingham, and D. Rampton, “BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment,” Thorax, vol. 60, no. 10, pp. 800–805, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. G. Maartens, P. A. Willcox, and S. R. Benatar, “Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults,” American Journal of Medicine, vol. 89, no. 3, pp. 291–296, 1990. View at Publisher · View at Google Scholar · View at Scopus
  43. J. E. Heffner and S. A. Sahn, “Salicylate-induced pulmonary edema. Clinical features and prognosis,” Annals of Internal Medicine, vol. 95, no. 4, pp. 405–409, 1981. View at Google Scholar · View at Scopus
  44. S. D. Goodwin and R. W. Glenny, “Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia: review of the literature and Food and Drug Administration Adverse Drug Reaction reports,” Archives of Internal Medicine, vol. 152, no. 7, pp. 1521–1524, 1992. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Turner-Warwick, “Adverse reactions affecting the lung: possible association with D-penicillamine,” Journal of Rheumatology, vol. 8, no. 7, pp. 166–168, 1981. View at Google Scholar · View at Scopus
  46. C. J. Eastmond, “Diffuse alveolitis as complication of penicillamine treatment for rheumatoid arthritis,” British Medical Journal, vol. 1, no. 6024, p. 1506, 1976. View at Google Scholar · View at Scopus
  47. H. Tomioka and T. E. King Jr., “Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 3, pp. 1011–1020, 1997. View at Google Scholar · View at Scopus
  48. P. Hilliquin, M. Renoux, S. Perrot, X. Puéchal, and C. J. Menkès, “Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis,” British Journal of Rheumatology, vol. 35, no. 5, pp. 441–445, 1996. View at Google Scholar · View at Scopus
  49. J. M. Kremer, G. S. Alarcón, M. E. Weinblatt et al., “Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review,” Arthritis and Rheumatism, vol. 40, no. 10, pp. 1829–1837, 1997. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Saravanan and C. A. Kelly, “Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis,” Rheumatology, vol. 43, no. 2, pp. 143–147, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. G. S. Alarcón, J. M. Kremer, M. Macaluso et al., “Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study,” Annals of Internal Medicine, vol. 127, no. 5, pp. 356–364, 1997. View at Google Scholar · View at Scopus
  52. G. J. Carroll, R. Thomas, C. C. Phatouros et al., “Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate,” Journal of Rheumatology, vol. 21, no. 1, pp. 51–54, 1994. View at Google Scholar · View at Scopus
  53. M. R. Golden, R. S. Katz, R. A. Balk, and H. E. Golden, “The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 22, no. 6, pp. 1043–1047, 1995. View at Google Scholar · View at Scopus
  54. C. Beyeler, B. Jordi, N. J. Gerber, and V. Im Hof, “Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study,” British Journal of Rheumatology, vol. 35, no. 5, pp. 446–452, 1996. View at Google Scholar · View at Scopus
  55. V. Cottin, J. Tébib, B. Massonnet, P. J. Souquet, and J. P. Bernard, “Pulmonary function in patients receiving long-term low-dose methotrexate,” Chest, vol. 109, no. 4, pp. 933–938, 1996. View at Google Scholar · View at Scopus
  56. C. Fuhrman, A. Parrot, M. Wislez et al., “Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 7, pp. 1186–1191, 2001. View at Google Scholar · View at Scopus
  57. A. Schnabel, K. Dalhoff, S. Bauerfeind, J. Barth, and W. L. Gross, “Sustained cough in methotrexate therapy for rheumatoid arthritis,” Clinical Rheumatology, vol. 15, no. 3, pp. 277–282, 1996. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Inokuma, H. Kono, Y. Kohno et al., “Methotrexate-induced lung injury in patients with rheumatoid arthritis occurs with peripheral blood lymphocyte count decrease,” Annals of the Rheumatic Diseases, vol. 65, no. 8, pp. 1113–1114, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. S. Imokawa, T. V. Colby, K. O. Leslie, and R. A. Helmers, “Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients,” European Respiratory Journal, vol. 15, no. 2, pp. 373–381, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. F. Salaffi, P. Manganelli, M. Carotti, S. Subiaco, G. Lamanna, and C. Cervini, “Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature,” Clinical Rheumatology, vol. 16, no. 3, pp. 296–304, 1997. View at Publisher · View at Google Scholar · View at Scopus
  61. C. S. Dayton, D. A. Schwartz, N. L. Sprince et al., “Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis,” American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 4, pp. 1189–1193, 1995. View at Google Scholar · View at Scopus
  62. J. K. Dawson, D. R. Graham, J. Desmond, H. E. Fewins, and M. P. Lynch, “Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests,” Rheumatology, vol. 41, no. 3, pp. 262–267, 2002. View at Google Scholar · View at Scopus
  63. D. A. Zisman, W. J. McCune, G. Tino, and J. P. Lynch, “Drug-induced pneumonitis: the role of methotrexate,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 18, no. 3, pp. 243–252, 2001. View at Google Scholar · View at Scopus
  64. D. Libby and D. A. White, “Pulmonary toxicity of drugs used to treat systemic autoimmune diseases,” Clinics in Chest Medicine, vol. 19, no. 4, pp. 809–821, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Suwa, M. Hirakata, S. Satoh, T. Mimori, K. Utsumi, and S. Inada, “Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy,” Clinical and Experimental Rheumatology, vol. 17, no. 3, pp. 355–358, 1999. View at Google Scholar · View at Scopus
  66. Y. Kamata, H. Nara, T. Kamimura et al., “Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction,” Internal Medicine, vol. 43, no. 12, pp. 1201–1204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. B. Chikura, S. Lane, and J. K. Dawson, “Clinical expression of leflunomide-induced pneumonitis,” Rheumatology, vol. 48, no. 9, pp. 1065–1068, 2009. View at Google Scholar · View at Scopus
  68. S. Suissa, M. Hudson, and P. Ernst, “Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 5, pp. 1435–1439, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. T. Sawada, S. Inokuma, T. Sato et al., “Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis,” Rheumatology, vol. 48, no. 9, pp. 1069–1072, 2009. View at Google Scholar · View at Scopus
  70. A. J. K. Ostor, A. J. Crisp, M. F. Somerville, and D. G. I. Scott, “Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab,” British Medical Journal, vol. 329, no. 7477, p. 1266, 2004. View at Google Scholar · View at Scopus
  71. K. Hagiwara, T. Sato, S. Takagi-Kobayashi, S. Hasegawa, N. Shigihara, and O. Akiyama, “Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 5, pp. 1151–1154, 2007. View at Google Scholar · View at Scopus
  72. W. G. Dixon, K. L. Hyrich, K. D. Watson, M. Lunt, and D. P. M. Symmons, “Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 1086–1091, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. M. Selman, “Hypersensitivity pneumonitis: a multifaceted deceiving disorder,” Clinics in Chest Medicine, vol. 25, no. 3, pp. 531–547, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. E. S. Yi, “Hypersensitivity pneumonitis,” Critical Reviews in Clinical Laboratory Sciences, vol. 39, no. 6, pp. 581–629, 2002. View at Publisher · View at Google Scholar · View at PubMed
  75. C. S. Glazer, C. S. Rose, and D. A. Lynch, “Clinical and radiologic manifestations of hypersensitivity pneumonitis,” Journal of Thoracic Imaging, vol. 17, no. 4, pp. 261–272, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. R. A. Roschmann and R. J. Rothenberg, “Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy,” Seminars in Arthritis and Rheumatism, vol. 16, no. 3, pp. 174–185, 1987. View at Google Scholar · View at Scopus
  77. R. Lazor, A. Vandevenne, A. Pelletier et al., “Cryptogenic organizing pneumonia: characteristics of relapses in a series of 48 patients,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 2, part 1, pp. 571–577, 2000. View at Google Scholar
  78. C. J. Zappala, P. I. Latsi, A. G. Nicholson et al., “Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 35, no. 4, pp. 830–835, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. R. W. Simms, C. K. Kwoh, L. G. Anderson et al., “Guidelines for monitoring drug therapy in rheumatoid arthritis: American College of Rheumatology Ad Hoc Committee on Clinical Guidelines,” Arthritis and Rheumatism, vol. 39, no. 5, pp. 723–731, 1996. View at Google Scholar · View at Scopus
  80. M. P. E. Puttick, A. V. Klinkhoff, A. Chalmers, and D. N. Ostrow, “Treatment of progressive rheumatoid interstitial lung disease with cyclosporine,” Journal of Rheumatology, vol. 22, no. 11, pp. 2163–2165, 1995. View at Google Scholar · View at Scopus
  81. M. Demedts, J. Behr, R. Buhl et al., “High-dose acetylcysteine in idiopathic pulmonary fibrosis,” New England Journal of Medicine, vol. 353, no. 21, pp. 2229–2242, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. N. Nanki, J. Fujita, Y. Yamaji et al., “Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamide to corticosteroids,” Internal Medicine, vol. 41, no. 10, pp. 867–870, 2002. View at Google Scholar · View at Scopus
  83. G. E. Tzelepis, S. P. Toya, and H. M. Moutsopoulos, “Occult connective tissue diseases mimicking idiopathic interstitial pneumonias,” European Respiratory Journal, vol. 31, no. 1, pp. 11–20, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. H. R. Collard, B. B. Moore, K. R. Flaherty et al., “Acute exacerbations of idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 7, pp. 636–643, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. T. Suda, Y. Kaida, Y. Nakamura et al., “Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases,” Respiratory Medicine, vol. 103, no. 6, pp. 846–853, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. S. A. Papiris et al., “Clinical review: idiopathic pulmonary fibrosis acute exacerbations—unravelling Ariadne's thread,” Critical Care, vol. 14, no. 6, p. 246, 2010. View at Google Scholar
  87. I. N. Park, D. S. Kim, T. S. Shim et al., “Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis,” Chest, vol. 132, no. 1, pp. 214–220, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. J. A. Bjoraker, J. H. Ryu, M. K. Edwin et al., “Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 1, pp. 199–203, 1998. View at Google Scholar · View at Scopus
  89. S. Mori et al., “Idiopathic interstitial pneumonia that responded to intermittent intravenous administration of high-dose cyclophosphamide,” Nihon Kyobu Shikkan Gakkai Zasshi, vol. 32, no. 10, pp. 983–989, 1994. View at Google Scholar
  90. T. Naniwa, H. Tomita, S. Ninomiya et al., “Successful use of immunosuppressive agents for the treatment of progressive rheumatoid interstitial lung disease: a case report,” Nihon Kokyuki Gakkai Zasshi, vol. 40, no. 1, pp. 55–60, 2002. View at Google Scholar · View at Scopus
  91. S. Ochi, T. Kubota, T. Sugihara et al., “A case report of rheumatoid arthritis complicated with rapidly progressive interstitial pneumonia, multiple bullae and pneumomediastinum, which was successfully treated with tacrolimus,” Nihon Rinsho Meneki Gakkai Kaishi, vol. 31, no. 1, pp. 62–67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. E. R. Fernández-Pérez, M. Yilmaz, H. Jenad et al., “Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease,” Chest, vol. 133, no. 5, pp. 1113–1119, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. H. Kubo, K. Nakayama, M. Yanai et al., “Anticoagulant therapy for idiopathic pulmonary fibrosis,” Chest, vol. 128, no. 3, pp. 1475–1482, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. J. J. Swigris, A. L. Olson, A. Fischer et al., “Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease,” Chest, vol. 130, no. 1, pp. 30–36, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. L. A. Saketkoo and L. R. Espinoza, “Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug,” Archives of Internal Medicine, vol. 168, no. 15, pp. 1718–1719, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. S. R. Atkins, C. Turesson, J. L. Myers et al., “Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia,” Arthritis and Rheumatism, vol. 54, no. 2, pp. 635–641, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. C. Popa, M. J. Leandro, G. Cambridge, and J. C. W. Edwards, “Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs,” Rheumatology, vol. 46, no. 4, pp. 626–630, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. S. W. Lim, D. Gillis, W. Smith, P. Hissaria, H. Greville, and C. A. Peh, “Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports,” Internal Medicine Journal, vol. 36, no. 4, pp. 260–262, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. O. Lambotte, R. Kotb, G. Maigne, F. X. Blanc, C. Goujard, and J. F. Delfraissy, “Efficacy of rituximab in refractory polymyositis,” Journal of Rheumatology, vol. 32, no. 7, pp. 1369–1370, 2005. View at Google Scholar · View at Scopus
  100. K. A. Keogh, S. R. Ytterberg, F. C. Fervenza, K. A. Carlson, D. R. Schroeder, and U. Specks, “Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 2, pp. 180–187, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. M. Koukoulaki, K. G. C. Smith, and D. R. W. Jayne, “Rituximab in Churg-Strauss syndrome,” Annals of the Rheumatic Diseases, vol. 65, no. 4, pp. 557–559, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus